OR WAIT null SECS
© 2021 MJH Life Sciences and Urology Times. All rights reserved.
© 2021 MJH Life Sciences™ and Urology Times. All rights reserved.
September 17, 2021
The TKI/immunotherapy combination demonstrated strong clinical activity in patients with metastatic or locally advanced urothelial carcinoma (mUC) harboring FGFR alterations.
September 14, 2021
Phase 1/2 data showed that large surface area microparticle docetaxel is safe with early signs of clinical activity in patients with high-risk non–muscle invasive bladder cancer.
September 11, 2021
Now that pivotal trials have demonstrated a survival benefit with PSMA-targeted therapy in metastatic prostate cancer, researchers are hoping to deliver the exciting new approach earlier in the disease course.